文献速递肝病

美国西班牙裔成人代谢功能障碍相关脂肪性肝病的差异:系统综述与Meta分析

Disparities for Hispanic Adults With Metabolic Dysfunction-associated Steatotic Liver Disease in the United States: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-07-16

该系统综述与Meta分析纳入22项研究共756,088名受试者(其中62,072名为西班牙裔),评估美国西班牙裔成人MASLD疾病负担与严重程度。西班牙裔成人MASLD汇总患病率为41%,MASH为61%,MASH相关进展性纤维化为27%,MASH肝硬化为5%。与非西班牙裔成人相比,西班牙裔成人MASLD的RR为1.50,MASH的RR为1.42。

要点

  • 美国西班牙裔成人MASLD汇总患病率为41%(95%CI 30%-52%)。
  • 西班牙裔成人MASH汇总患病率为61%(95%CI 39%-82%)。
  • 与非西班牙裔成人相比,西班牙裔成人MASLD的RR为1.50(95%CI 1.32-1.69)。

核心结论

  • 美国西班牙裔成人的健康差异持续加重,其MASLD和MASH的相对风险显著高于非西班牙裔成人。
  • 作者认为迫切需要开展公共卫生工作以优化西班牙裔成人人群的筛查和照护服务。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase和Cochrane数据库,遵循PRISMA指南。
  • 纳入2010年至2023年12月的研究,排除重叠队列,采用随机效应模型估计汇总患病率和相对风险(RR)及95%CI。
  • 共纳入22项研究,合计756,088名受试者,其中62,072名为西班牙裔。

主要发现

  • 美国西班牙裔成人MASLD汇总患病率为41%(95%CI 30%-52%)。
  • 美国西班牙裔成人MASH汇总患病率为61%(95%CI 39%-82%)。
  • 美国西班牙裔成人MASH相关进展性纤维化汇总患病率为27%(95%CI 15%-39%)。
  • 美国西班牙裔成人MASH肝硬化汇总患病率为5%(95%CI 1%-8%)。
  • 与非西班牙裔成人相比,西班牙裔成人MASLD的RR为1.50(95%CI 1.32-1.69),MASH的RR为1.42(95%CI 1.04-1.93),MASH相关进展性纤维化的RR为1.37(95%CI 0.96-1.96),MASH肝硬化的RR为0.93(95%CI 0.49-1.77)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Prevalence and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) is reported to be higher in Hispanic adults in the United States (U.S.), although rates vary substantially across studies and have increased given the evolving obesity epidemic. This systematic review and meta-analysis quantifies MASLD disease burden and severity in contemporary cohorts to characterize health disparities experienced by adult Hispanic individuals in the U.S. METHODS: We searched the MEDLINE, Embase, and Cochrane databases per the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Studies from 2010 to December 2023 were included to capture data representative of current populations given the obesity epidemic. Studies from overlapping cohorts were excluded. Meta-analyses were conducted using random-effects models to estimate pooled prevalence and relative risk (RR) with 95% confidence intervals (CIs). RESULTS: We identified 22 studies, comprising 756,088 subjects, of which 62,072 were Hispanic. The pooled prevalence in U.S. Hispanic adults was 41% (95% CI, 30%-52%) for MASLD, 61% (95% CI, 39%-82%) for metabolic dysfunction-associated steatohepatitis (MASH), 27% (95% CI, 15%-39%) for MASH-associated advanced fibrosis (AF), and 5% (95% CI, 1%-8%) for MASH cirrhosis. Compared with non-Hispanic adults, Hispanic adults had a RR of 1.50 (95% CI, 1.32-1.69) for MASLD, 1.42 (95% CI, 1.04-1.93) for MASH, 1.37 (95% CI, 0.96-1.96) for MASH-associated AF, and 0.93 (95% CI, 0.49-1.77) for MASH cirrhosis. CONCLUSION: Health disparities for U.S. Hispanic adults continue to worsen with significantly higher relative risk of MASLD and MASH compared with non-Hispanic adults. Public health efforts to optimize screening and care delivery for the adult Hispanic population are urgently needed.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Tesfai K, Pace J, El-Newihi N, et al. Disparities for Hispanic Adults With Metabolic Dysfunction-associated Steatotic Liver Disease in the United States: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2024. PMID: 39025254. doi:10.1016/j.cgh.2024.06.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。